Artificial intelligence-powered cancer diagnostics startup OneCell Diagnostics raised $16 million in an oversubscribed series A funding round led by Celesta Capital.
Other participants in the funding round included Tenacity Ventures, Cedars Sinai, Eragon, and Singularity Ventures.
The company, which has developed cutting-edge technology for precision oncology liquid biopsy diagnostics and is headquartered in India and Silicon Valley, said the funding will be used to advance its vision of democratising precision oncology through cancer diagnostic testing that is more accessible, actionable, and affordable.
With this funding, it will expand to the US market with its next-generation liquid biopsy test called OncoIndx Alfa, which detects circulating tumour cells which offer rich biomarkers that advance precision diagnosis and treatment of cancer for use cases including treatment response monitoring, disease progression, recurrence, and more.
Further, Celesta Capital founding managing partner Michael Marks and Nobel Laureate and Celesta Capital senior advisor James Rothman will join the OneCell board of directors.
“We see a future where everyone has access to high-quality, life-saving cancer testing and this funding is a powerful validation of our vision,” said Mohan Uttarwar, cofounder and CEO, OneCell Diagnostics.
“By integrating our single-cell multi-omics analytics with next-generation liquid biopsy approaches, we have the opportunity to break new ground in delivering accurate, personalised cancer care worldwide.”
In India, the company has already introduced a series of products and tested its cell biopsy technology in nearly 10,000 patients to date.
OneCell partners with All India Institute of Medical Science, New Delhi, and Tata Memorial Centre, as per its website. It also has strategic academic and industry partners including Harvard Medical School and Stanford University, among others.
“Celesta is excited about differentiated companies sitting at the intersection of high tech and biomedical science, and OneCell fits this mould perfectly,” said Marks.
“By leveraging the strategic benefits of the US-India corridor, OneCell is well-positioned to continue building competitive advantages. We pride ourselves on being active value-add investors and Celesta will tap our ecosystem to support their growth wherever possible.”
Rothman said he is joining the board at a pivotal time in the arc of innovation for cancer treatment, with cell biopsy representing a groundbreaking shift in the approach to diagnostics which creates more opportunities for highly individualised care.
“This technology has the potential to reshape the oncology landscape, and we are eager to support OneCell’s bold mission to reach more than 1,000 oncologists and one million patients in the near future,” Rothman added.
Founded in 2021, OneCell’s proprietary technology leverages a combination of next-generation sequencing in combination with strong bioinformatics, AI/ML, and data analytics for multi-omics biomarkers.
Other participants in the funding round included Tenacity Ventures, Cedars Sinai, Eragon, and Singularity Ventures.
The company, which has developed cutting-edge technology for precision oncology liquid biopsy diagnostics and is headquartered in India and Silicon Valley, said the funding will be used to advance its vision of democratising precision oncology through cancer diagnostic testing that is more accessible, actionable, and affordable.
With this funding, it will expand to the US market with its next-generation liquid biopsy test called OncoIndx Alfa, which detects circulating tumour cells which offer rich biomarkers that advance precision diagnosis and treatment of cancer for use cases including treatment response monitoring, disease progression, recurrence, and more.
Further, Celesta Capital founding managing partner Michael Marks and Nobel Laureate and Celesta Capital senior advisor James Rothman will join the OneCell board of directors.
“We see a future where everyone has access to high-quality, life-saving cancer testing and this funding is a powerful validation of our vision,” said Mohan Uttarwar, cofounder and CEO, OneCell Diagnostics.
“By integrating our single-cell multi-omics analytics with next-generation liquid biopsy approaches, we have the opportunity to break new ground in delivering accurate, personalised cancer care worldwide.”
In India, the company has already introduced a series of products and tested its cell biopsy technology in nearly 10,000 patients to date.
OneCell partners with All India Institute of Medical Science, New Delhi, and Tata Memorial Centre, as per its website. It also has strategic academic and industry partners including Harvard Medical School and Stanford University, among others.
“Celesta is excited about differentiated companies sitting at the intersection of high tech and biomedical science, and OneCell fits this mould perfectly,” said Marks.
“By leveraging the strategic benefits of the US-India corridor, OneCell is well-positioned to continue building competitive advantages. We pride ourselves on being active value-add investors and Celesta will tap our ecosystem to support their growth wherever possible.”
Rothman said he is joining the board at a pivotal time in the arc of innovation for cancer treatment, with cell biopsy representing a groundbreaking shift in the approach to diagnostics which creates more opportunities for highly individualised care.
“This technology has the potential to reshape the oncology landscape, and we are eager to support OneCell’s bold mission to reach more than 1,000 oncologists and one million patients in the near future,” Rothman added.
Founded in 2021, OneCell’s proprietary technology leverages a combination of next-generation sequencing in combination with strong bioinformatics, AI/ML, and data analytics for multi-omics biomarkers.